Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT00217477
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT00182806
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00112892
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00107315
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2005-01-07
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT00100815
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈCase Comprehensive Cancer Center, Cleveland, Ohio, United States
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT00096044
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-10-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 43
- Registration Number
- NCT00096018
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00096330
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
Phase 1
Terminated
- Conditions
- Esophageal Cancer
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00093652
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Leukemia
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 61
- Registration Number
- NCT00093483
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States